RxDoctor Payments Data

John Anderson, DO

Clinical Cardiac Electrophysiology · Duluth, MNNPI 1124431051

Payments from drug & device makers

What this record shows

This record is dominated by grants: $37,294 of the $43,595 with a category attached, or 85.5%. Medtronic accounts for 67.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2020 at $25,233 and has fallen 99.1% since, to $238 in 2025.

$43,595in general payments, 2019–2025

Across 104 payments — averaging $419.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Boston Scientific$11K
  • Abbott$3K
  • AbbVie$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$111
  • Biotronik Inc.$99
  • plus $82 from 2 others

What the payments were for

  • Grants$37,29486%
  • Travel & lodging$1,5844%
  • Food & beverage$4,0989%
  • Education$4891%
  • Gifts$1300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,595 in reported general payments places this provider in the 80th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

See all clinical cardiac electrophysiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$148,772
Medicare patients
907
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$54,053
XareltoRivaroxaban29$29,735
Flecainide Acetate57$2,935
Amiodarone Hcl64$1,544
Metoprolol Succinate70$1,455
Dofetilide11$1,378
SotalolSotalol Hcl15$252
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$54,05351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

Other clinical cardiac electrophysiology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →